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A B S T R A C T
The ground state of pluripotency is deﬁned as a minimal unrestricted epigenetic state as present in the Inner Cell
Mass. Mouse embryonic stem cells (ESCs) grown in a deﬁned serum-free medium with two kinase inhibitors (“2i
ESCs”) have been postulated to reﬂect ground-state pluripotency, whereas ESCs grown in the presence of serum
(“serum ESCs”) share more similarities with post-implantation epiblast cells. Pluripotency results from an in-
tricate interplay between cytoplasmic, nuclear and chromatin-associated proteins. Here, we perform quantitative
subcellular proteomics to gain insight in the molecular mechanisms sustaining the pluripotent states reﬂected by
2i and serum ESCs. We describe a full SILAC workﬂow and quality controls for proteomic comparison of 2i and
serum ESCs, allowing subcellular proteomics of the cytoplasm, nucleoplasm and chromatin. The obtained
quantitative information revealed increased levels of naïve pluripotency factors on the chromatin of 2i ESCs.
Surprisingly, the cytoplasmic proteome suggests that 2i and serum ESCs utilize distinct metabolic programs,
which include upregulation of free radical buﬀering by the glutathione pathway in 2i ESCs. Through induction of
intracellular radicals, we show that the altered metabolic environment renders 2i ESCs less sensitive to oxidative
stress. Altogether, this work provides novel insights into the proteomic landscape underlying ground state
pluripotency.
1. Introduction
Embryonic stem cells (ESCs) are pluripotent cells derived from the
Inner Cell Mass (ICM) of the blastocyst. Conventionally, mouse ESCs
were derived and maintained in culture media containing serum and
leukemia-inhibitory factor (LIF; “serum ESCs”), which maintain plur-
ipotency via JAK/STAT3 and SMAD signaling (Evans and Kaufman,
1981; Martin, 1981). About ten years ago, a deﬁned minimal culture
condition for ESC maintenance has been pioneered relying on two
small-molecule inhibitors of the mitogen-activated protein kinase
(MEK) and glycogen-synthase kinase (GSK3), respectively (“2i
ESCs”; Ying et al., 2008). 2i and serum ESCs have been shown to be
distinct in their transcriptome and epigenome (Ficz et al., 2013; Habibi
et al., 2013; Joshi et al., 2015; Leitch et al., 2013; Marks et al., 2012;
von Meyenn et al., 2016; Walter et al., 2016; Weinberger et al., 2016).
Due to the high resemblance of 2i ESCs to pre-implantation ICM cells in
the embryo, it was postulated that 2i ESCs exist in a distinct state of
pluripotency, the so-called “ground state”. On the other hand, the hy-
permethylated serum ESCs exist in a metastable state that shares fea-
tures with the more primed early post-implantation embryo (Wray
et al., 2010; Ying et al., 2008).
Recent work implicated that, next to the features mentioned above,
also the proteome between 2i and serum ESCs is markedly diﬀerent. For
example, it was shown that 2i ESCs are hallmarked by higher levels of
core pluripotency factors such as PRDM14, KLF2, KLF4 and NANOG,
which is in correspondence to the ‘enhanced’ pluripotency of 2i ESCs
(Walter et al., 2016; Weinberger et al., 2016; Yamaji et al., 2013; Yeo
et al., 2014). On the other hand, serum ESCs possess higher levels of de
novo methyltransferases (DNMTs) and UHRF1, resulting in higher DNA
methylation, and increased levels of focal adhesion and cytoskeletal
proteins, all signs of early developmental priming (Habibi et al., 2013;
Taleahmad et al., 2017). As pluripotency results from an intricate in-
terplay between cytoplasmic, nuclear and chromatin-associated pro-
teins, the subcellular distribution of proteins can greatly aﬀect the
pluripotent state. A notable example comprises the transcription factor
TFE3, an important regulator for ESRRB. TFE3 localizes in both the
cytoplasm and nucleus in 2i ESCs, but is sequestered into the cytoplasm
upon 2i withdrawal resulting in developmental priming (Betschinger
et al., 2013). Other examples include the Hippo signaling mediators
YAP and TAZ, that sustain primed pluripotency when present in the
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cytoplasm, but induce diﬀerentiation upon nuclear translocation (Zhou
et al., 2017). To further extend our understanding of the molecular
mechanisms and pathways that deﬁne the pluripotent ground state,
quantitative information of the (subcellular) proteomic landscape is
critical.
To obtain quantitative proteome information, it is important to
minimize variations introduced during sample handing, in particular
for subcellular proteomics. Therefore, early mixing of samples during
the experimental workﬂow is highly preferable. One of the most pow-
erful approaches for high-throughput quantitative proteomics that al-
lows for early mixing represents Stable Isotope Labeling with Amino
acids in Cell culture (SILAC). SILAC relies on the labeling of proteins
with heavy versions of arginine and lysine (the ‘heavy’ sample). Before
downstream processing, cell pellets of a heavy labeled sample can be
mixed with cell pellets from a sample in which the proteins contain
normal arginine and lysine (the ‘light’ sample), after which the mass
spectrometer can discriminate between light- and heavy-labeled pro-
teins based on mass. Notably, SILAC labeling approaches for proteomic
characterization of 2i and serum ESCs have not been described thus far.
Here, we provide quantitative information on the subcellular pro-
teomes of 2i and serum ESCs using an optimized SILAC workﬂow. We
ﬁrst conﬁrm that SILAC labeled 2i ESCs have preserved their self-re-
newing status as well as pluripotent characteristics based on well-
known markers and show that we can robustly generate whole cell
proteomes of 2i and serum ESCs using our SILAC approach. Next, we
apply our workﬂow to generate subcellular proteomes of the cytoplasm,
nucleoplasm and chromatin-bound fraction of 2i and serum ESCs. Using
the information of the proteins as quantiﬁed by this approach we pre-
sent evidence that 2i ESCs are hallmarked by increased nuclear and
chromatin levels of naïve transcription factors such as KLF4.
Furthermore, the cytoplasmic proteome suggests that the activity of
several metabolic pathways between 2i and serum ESCs is changed.
Interestingly, these diﬀerential pathways render 2i ESCs more resistant
to metabolic stress compared to serum ESCs. Altogether, this work
provides quantitative insights into the subcellular proteome landscape
of the pluripotent ground state.
2. Experimental procedures
2.1. ES Cell culture and SILAC labeling
E14 ESCs (129/Ola background) were maintained in Dulbecco's
Modiﬁed Eagle Medium (DMEM) containing 15% fetal bovine serum,
5 μM beta mercaptoethanol (Sigma) and Leukemia inhibitory factor
(LIF; 1000 U/ml) (Millipore), referred to as serum ESCs, or in serum-
free N2B27 (also called Ndiﬀ) supplemented with PD0325901 (1 μM),
CH99021 (3 μM) and LIF (1,000 U/ml), referred to as 2i ESCs. The ESCs
have been derived in serum conditions and were adapted to 2i culture.
For SILAC labeling, 2i ESCs were grown in customized Ndiﬀ (without
Arginine and Lysine; Stem Cell Sciences) supplemented with 13C615N4
L-arginine and 13C615N2 L-lysine (Isotec). The absence of light arginine
and lysine in the SILAC medium was veriﬁed using ion exchange
chromatography (Fig. S1). Cells were grown in SILAC medium for at
least 8 population doublings to ensure full incorporation of the heavy
labeled aminoacids. For ROS induction experiments, cells were allowed
to attach overnight prior to exposure to the various compounds. H2O2
was used at a range of concentrations and 150 μM for ROS induction.
Doxorubicin was used at 500 nM and 1 μM for survival assays and
500 nM for ROS induction. 5-azacytidine was used at 500 nM and 1 μM
for survival assays and 1 μM for ROS induction. MG132 was used at
5 μM for both survival and ROS induction assays. For survival assays,
inhibitors were added for 20 h (MG132 for 6 h) and for ROS induction
ESCs were exposed for 3 h. When DMSO was used as a control, the ﬁnal
DMSO concentration was the same as in compound-treated cells
(compounds were dissolved in DMSO and further diluted in PBS).
2.2. Subcellular fractionation
Extracts were prepared as described in Dignam et al. (1983). Cells
were harvested with trypsin and washed with PBS. An equal number of
heavy-labeled 2i ESCs and non-labeled serum ESCs (grown in regular
serum medium) were mixed and pelleted at 400 g for 5min at 4 °C. The
resulting cell pellets were incubated for 10min at 4 °C in ﬁve volumes
of Buﬀer A (10mM Hepes-KOH (pH 8.0), 1.5 mM MgCl2, 10mM NaCl)
and centrifuged at 400g for 5min at 4 °C. Cells were resuspended in two
volumes of Buﬀer A plus protease inhibitors (Roche) and 0.15% NP-40
and transferred to a Dounce homogenizer. After douncing 30–40
strokes with a Type B pestle, the lysates were centrifuged at 3,200g for
15min at 4 °C. After centrifugation, the supernatant was taken as the
cytoplasmic extract. The nuclear pellet was washed twice with PBS and
nuclei were pelleted at 3200g for 5min at 4 °C. The nuclear pellet was
resuspended in 2 volumes Buﬀer C (420mM NaCl, 20mM Hepes-KOH
(pH 8.0), 20% v/v glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.1% NP-40)
supplemented with protease inhibitors and 0.5mM DTT. This solution
was rotated for 1 h at 4 °C, and then spun at 20,800g for 45min at 4 °C.
The supernatant was taken as the nuclear fraction and stored at−80 °C
until further use. To obtain the chromatin fraction, the insoluble
chromatin pellet was resuspended in four volumes of Radio Im-
munoprecipitation buﬀer (RIPA) (150mM NaCl, 1% NP-40, 0.5%
NaDOC, 0.1% SDS, 50mM Tris (pH=8)) and brieﬂy sonicated to so-
lubilize the chromatin fraction and stored at −80 °C until further use.
2.3. RT-qPCR
Total RNA was isolated using a RNeasy mini kit (Invitrogen). cDNA
was synthesized using random hexamers and RT-qPCR was performed
using iQ SYBR Green Supermix (Bio-Rad) on a CFX96 Real-Time System
C1000 Thermal Cycler (Bio-Rad).
2.4. Western blot
Protein extracts were denatured in 4× SDS loading dye and sepa-
rated on a 12% SDS-PAGE gel. Separated proteins were transferred onto
a PVDF membrane for staining with primary and secondary antibodies.
Primary antibodies used were mouse anti-ACTB (Abcam; #8226),
Rabbit anti-Topoisomerase 1 (Abcam; #109374), rabbit anti-HDAC2
(Abcam; #7029) and Rabbit anti-H3K9me3 (Abcam; #8898). Protein
bands were visualized using Pierce Western Blotting Substrate (Thermo,
#32209) according to the manufacturer's instructions.
2.5. (Hydroxy)methylation measurements of genomic DNA
Genomic DNA was isolated using the Wizard genomic DNA isolation
kit (Promega). Mass spectrometry analysis of the nucleosides was per-
formed on genomic DNA digested using DNA Degradase Plus (Zymo
Research). Levels of (hydroxy)methylation were quantiﬁed via liquid
chromatography-tandem mass spectrometry (LC-MS) as described in
Kroeze et al., 2014.
2.6. Generation of whole cell extracts
Cell pellets were resuspended in RIPA buﬀer supplemented with
protease inhibitor at a density of 10,000 cells/μl and sonicated for
2 cycles (30 s ON, 30 s OFF) on a Biorupter (Diagenode) to solubilize the
cells.
2.7. Mass spectrometry and data analysis
Whole cell, cytoplasmic, nuclear and chromatin extracts were de-
natured using Filter Aided Sample Preparation (FASP) and digested
using Trypsin/LysC. Trypsin digests were desalted using Stage Tips
prior to mass spectrometry measurements. Mass spectra were recorded
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on an LTQ-Orbitrap QExactive mass spectrometer (Thermo Fisher
Scientiﬁc) using a 4-h acetonitrile gradient, selecting the top 10 most
intense precursor ions for fragmentation. Thermo Raw MS ﬁles were
analyzed using the MaxQuant software version 1.5.1.0 and searched
against the curated UniProtKB mouse proteome (Cox et al., 2014; Cox
and Mann, 2008). Default MaxQuant settings were used with the fol-
lowing modiﬁcations: multiplicity was set to 2, Arg10 and K8 were
selected as heavy labels, match between runs and requantify were en-
abled. Downstream analysis of proteomics data was performed using
Perseus (Tyanova et al., 2016) and in-house R scripts. Diﬀerential
proteins were calculated using the Signiﬁcance B feature in Perseus
based on the normalized H/L ratios (threshold at p < 0.05) (Cox and
Mann, 2008). For an overview of the pathways sustaining 2i and serum
ESCs, the main eﬀector proteins were obtained from Hackett and Azim
Surani, 2014. The cytoplasmic proteomes were used to obtain cyto-
plasmic ratios. As fold changes of the pluripotency factors in the nu-
cleus and the chromatin were similar, we used the ratios of the chro-
matin for the nuclear / chromatin compartment. For a complete
overview, the levels of important eﬀector proteins that were not de-
tected in our MS data were inferred from literature.
2.8. Quantiﬁcation of intracellular ROS and glutathione
ROS levels were quantiﬁed using the DCFDA Cellular ROS Detection
Assay Kit (Abcam, #ab113851) according the manufacturer's instruc-
tions. Total glutathione levels were quantiﬁed using the Glutathione
Fluorometric Assay Kit (Biovision, #K264-100) according the manu-
facturer's instructions.
2.9. RNAseq analysis
Gene expression counts of preimplantation embryos (E2.5, E3,5,
E4.5) and postimplantation embryos (E5.5) were obtained from
Boroviak et al., 2015. Counts for the genes (of which the proteins were
detected in our SILAC workﬂow) that are related to ROS scavenging
were extracted and Z-score normalized using R3.3.2. Genes with a peak
expression (=highest Z-score) at E2.5-E4.5 were considered enriched in
the preimplantation stage and those with a peak expression (=highest
Z-score) at E5.5 were considered enriched in the postimplantation
stage.
2.10. Data accessibility
The proteomic datasets are available from the ProteomeXchange
Consortium via PRIDE submission with the dataset identiﬁer
PXD009217.
3. Results
3.1. The use of SILAC for whole proteome comparison between 2i and
serum ESCs
SILAC-based approaches generally require dialysis of serum to re-
move the natural arginine and lysine amino acids. During this process,
other low-molecular factors including growth factors are removed as
well, which might interfere with the cellular identity of sensible cell
types (Xie et al., 2014). To measure the proteomes of 2i and serum ESCs
using SILAC, we took advantage of the serum-free growth conditions of
2i ESCs. For the SILAC experiments, we cultured 2i ESCs in custom
deﬁned medium lacking regular arginine and lysine (Fig. S1) but sup-
plemented with heavy lysine and arginine. The “heavy” labeling of 2i
ESCs allows for a SILAC-based comparison to serum ESCs that are
grown in normal medium (i.e. ‘light’ labeled). First, we evaluated
whether culturing in SILAC medium did not result in unanticipated
changes to the 2i ESCs. During culturing for multiple passages, the 2i
ESCs retained their typical round morphology (Fig. 1A) (Ying et al.,
2008). Also, the growth rate of 2i ESCs in normal medium or SILAC
medium supplemented with either ‘light’ (‘normal’) or ‘heavy’ amino
acids was similar (Fig. 1B). In light of the fact that global DNA hypo-
methylation is a major hallmark of 2i ESCs (Habibi et al., 2013), we
measured the DNA methylation levels of SILAC 2i ESCs using mass
spectrometry. This revealed that 2i ESCs in both normal medium and
SILAC medium exhibit a similar degree of DNA hypomethylation
(Fig. 1C). Finally, we measured the expression of key pluripotency
factors Oct4, Nanog, Rex1 and the stem cell maintenance gene Prdm16
using RT-qPCR. This showed that the expression of these genes is not
aﬀected by the SILAC medium formulation (Fig. 1D). Altogether, this
indicates that the SILAC medium does not largely aﬀect the pluripotent
state of 2i ESCs.
Next, we evaluated the eﬃciency of labeling with heavy amino
acids of 2i ESCs grown in SILAC medium (Fig. 1E). We performed a
single LC-MS experiment of 2i ESCs grown in heavy medium for six
passages and inspected the heavy/light ratios in this sample. This led to
a unimodal distribution of high incorporation ratios of heavy amino
acids (incorporation rate > 97%), demonstrating that 2i ESCs can be
eﬃciently labeled. We also queried the spectra for heavy proline in
light of recent work reporting conversion of heavy arginine to heavy
proline (Van Hoof et al., 2007). However, at the arginine concentration
used for the current study we did not detect any signiﬁcant conversion
of heavy arginine into heavy proline (data not shown). Finally, to test
the reproducibility of the workﬂow, we generated SILAC proteomes of
two independent experiments. This allowed quantiﬁcation of over 4000
proteins with high reproducibility (R=0.88) between the experiments,
as well as the identiﬁcation of diﬀerential proteins (Fig. 1F,G). Alto-
gether, we concluded that our SILAC workﬂow is robust and applicable
for quantitative proteomics of 2i and serum ESCs.
3.2. Subcellular proteomes of 2i and serum ESCs using SILAC
An important advantage of SILAC over other MS approaches such as
label-free quantiﬁcation (LFQ) or dimethyl labeling is the possibility of
early mixing of diﬀerent cell populations, which minimizes variations
introduced by sample preparation prior to LC-MS analysis (Lau et al.,
2014). As such, SILAC is highly suitable for LC-MS experiments that
require subcellular fractionation. To obtain subcellular information of
2i and serum ESCs, we separated the cytoplasm, nuclei and chromatin
of SILAC-labeled 2i ESCs and serum ESCs (Fig. 2A). We validated proper
separation of the fractions using western blot for known protein mar-
kers that are mainly cytoplasmic (b-actin), nuclear (Topoisomerase I),
nuclear and chromatin-associated (HDAC2) and chromatin only
Fig. 1. Validation of proteomics by the use of SILAC in 2i and serum ESCs. A) Cell morphology of 2i ESCs grown in regular or SILAC medium for 12 days. B)
Cumulative cell number of 2i ESCs grown in regular medium or in SILAC medium supplemented with light (‘normal’) or heavy amino acids for several passages. C)
Representative DNA methylation percentages as measured by LC-MS. Serum ESCs are included as control and are known to be globally hypermethylated (Habibi
et al., 2013). D) Delta Ct values relative to Gapdh from qPCR measurements of the same cells as in (B). E) Distribution of peptide ratios of a single shot LC-MS run of
heavy labeled 2i ESCs. F) Ratio heavy / light of two independent SILAC whole proteome measurements of 2i and serum ESCs. Pearson correlation between the two
replicates is indicated in left top. Blue dots are proteins signiﬁcantly higher in serum ESCs in both replicates and green dots are proteins signiﬁcantly higher in 2i ESCs
(p < 0.05; signiﬁcance B). Proteins that are analyzed in Fig. 1G are labeled by their name. G) Representative SILAC spectra for a peptide derived from GAPDH (equal
between 2i and serum), UTF1 (higher serum) and GSS (higher 2i). Y-axis indicates intensity, x-axis represent mass/charge values. Blue triangle indicates elution from
the light peptide (“serum-ESC derived”) and the green triangle indicates the heavy peptide (“2i derived”) as in Fig. 2A. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)
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(H3K9me3) (Fig. 2B). After mass spectrometry, gene ontology (GO)
analysis of the proteins as identiﬁed within each of the fractions re-
vealed GO-terms relevant to the speciﬁc subcellular fractions: these
included mainly metabolic terms for the cytoplasmic fraction, RNA-
splicing and transport for the nuclear fraction and chromatin-mod-
iﬁcation and gene expression for the chromatin fraction (Fig. 2C).
Taken together, this demonstrates that the subcellular fractions were
adequately separated.
For all three fractions, we identiﬁed up to 2300 proteins per fraction
with high reproducibility (Fig. 2D, E). Focusing on diﬀerential proteins
(p < 0.05 in both replicates), 158 proteins were signiﬁcantly diﬀerent
in both replicates between 2i and serum ESCs in the cytoplasmic frac-
tion, 192 in the nuclear fraction and 131 in the chromatin fraction
(Fig. 2D; Supplementary Table 1). Notably, we observed limited overlap
in detected and diﬀerential proteins between the various fractions
(Fig. 2E, F), further highlighting the importance of subcellular fractio-
nation. The diﬀerential proteins that we identify included notable
markers for ground state pluripotency such as DAZL, ESRRB and
TFCP2l1 enriched in 2i ESCs. Proteins signiﬁcantly enriched in serum
ESCs include the DNA methylation associated DNMT3A/B/L and
UHRF1, which is in line with the higher DNA methylation levels in
serum ESCs, as well as the early-diﬀerentiation associated proteins
LIN28A and UTF1, which is in agreement with the metastable state of
serum ESCs (Fig. 2D; Supplementary Table 1) (Galonska et al., 2014;
Zhang et al., 2016). Also GO terms related to the diﬀerential proteins
included priming-related terms for serum ESCs such as embryo devel-
opment and neural tube closure in the nucleoplasm and DNA methy-
lation for the chromatin-associated proteins (Fig. 2D). We also eval-
uated the levels of the factors TFE3 and YAP1 (as mentioned in the
introduction). TFE3 was present in the cytoplasm and nucleus of 2i and
serum ESCs, in line with previous reports (Supplementary Table 1). We
also observed YAP in all fractions in 2i and serum ESCs, which seems to
be tolerated by the undiﬀerentiated ESCs. In summary, these results
show that the SILAC workﬂow is suitable to obtain subcellular pro-
teomes of 2i and serum ESCs with high resolution.
3.3. SILAC identiﬁes pluripotency modules enriched in ground state
pluripotency
The quantitative information obtained on the subcellular proteome
of 2i and serum ESCs provides the unique opportunity to investigate
how the diﬀerentially activated pathways in the cytoplasm aﬀect the
abundance of individual members of the core pluripotency network on
the chromatin. First, we inspected the cytoplasmic levels of the direct
targets of extracellular signaling cues, which comprise SMAD1/5/8 and
STAT3 in serum ESCs and GSK3, STAT3 and ERK1/2 in 2i ESCs
(Hackett and Azim Surani, 2014). The total abundance of these proteins
is not diﬀerent between 2i and serum ESCs (Fig. 3), which is in line with
previous reports showing the state of phosphorylation and/or the ca-
pacity to phosphorylate is aﬀected rather than the abundance of these
proteins (Ying et al., 2008). Next, we focused on the abundance of the
core pluripotency network on the chromatin making use of a compre-
hensive list of pluripotency factors (Dunn et al., 2014). This revealed
that the levels of OCT4 and SOX2 are equal between 2i and serum ESCs,
which ﬁts with their fundamental importance for the maintenance of
pluripotency (Masui et al., 2007). The pluripotency factor REX1 was
also similarly present on the chromatin in 2i and serum ESCs. We ob-
served that, although LIF is present in the culture conditions of both 2i
and serum ESCs, the main downstream eﬀectors KLF4 and TFCP2L1
were strongly enriched in 2i ESCs, suggesting their expression level is
aﬀected by factors other than LIF (Fig. 3). Further, we noted 2i ESCs are
hallmarked by increased levels of the ESRRB, which is the key target of
b-catenin (Martello et al., 2012), TBX3 and NANOG. Individually these
factors are dispensable for the maintenance of pluripotency, but they
strengthen the pluripotency network (Dunn et al., 2014). Hence, the
increased chromatin occupancy of these factors is in line with previous
observations on the pluripotent state of 2i ESCs (Wray et al., 2010).
Interestingly, we observed that the ancillary factors KLF5 and SALL4
are enriched on the chromatin in serum ESCs (Fig. 3). Removal of KLF5
and SALL4 results in diﬀerentiation of serum ESCs, whereas at least
SALL4 ablation is well tolerated by 2i ESCs. This suggests that these
factors become more important upon dissolution of the pluripotent
state (Ema et al., 2008; Miller et al., 2016). Altogether, these analyses
reveal that the pluripotency network is plastic and changes between
pluripotent states.
3.4. Ground state and metastable pluripotency are supported by distinct
metabolic programs
Next to epigenetic changes, changes on the metabolic level are
starting to be uncovered between 2i and serum ESCs (Carey et al.,
2015). Subcellular fractionation brings lower abundant metabolic
proteins into the dynamic range of the mass spectrometer, allowing to
comprehensively proﬁle proteins belonging to metabolic pathways
(Paulo et al., 2013). To obtain a detailed overview of the metabolic
pathways that distinguish 2i and serum ESCs, we analyzed the diﬀer-
ential proteins in the cytoplasmic fraction for metabolic gene ontology
(GO) terms using the Metaboanalyst software (Xia et al., 2015). This
revealed that GO terms characterizing 2i ESCs were mainly related to
fatty acid and sugar metabolism, whereas GO-terms related to serum
ESCs included acetyl-CoA biosynthesis and glycolysis (Fig. 4A). The
enrichment of glycolysis factors in serum ESCs, as exempliﬁed by the
upregulation of key factors PDK1, LDHA and ZIC3, ﬁts with their me-
tastable state as the enhancement of glycolysis is a hallmark for in-
duction of primed pluripotency (Fig. 4B) (Zhou et al., 2012). Interest-
ingly, we observed that one of the top enriched terms in 2i ESCs is
glutathione metabolism (Fig. 4A; indicated in red). Together with
Catalase (Cat), Peroxiredoxins (PRX) and Thioredoxins (TRX), the
Glutathione system is of critical importance for reducing oxidative
stress by scavenging free radicals such as H2O2. This is established
through glutathione (GSH), which is oxidized by free radicals towards
glutathione disulﬁde (GSSG) that can be actively reduced to GSH
(Fig. 4C) (Filomeni et al., 2002). Most of the scavenging proteins in-
volved in glutathione metabolism as well as catalase are signiﬁcantly
upregulated in 2i ESCs (Fig. 4C). To investigate whether the upregu-
lated glutathione pathway proteins are also reﬂected in the amount of
glutathione, we measured the total levels of the glutathione (the sum of
GSH and GSSG). This was similar between 2i and serum ESCs (Fig. 4D).
As the glutathione pathway is involved in ROS scavenging and 2i ESCs
are characterized by upregulation of metabolic programs, this could
result in increased reactive oxygen species (ROS) levels as these are by-
products of metabolic processes (Ray et al., 2012). Therefore we
Fig. 2. Generation of subcellular proteomes using SILAC. A) Schematic workﬂow for subcellular fractionation of 2i and serum ESCs. B) Western blot analysis of the
subcellular fractionation of two independent SILAC experiments. C) GO terms of proteins enriched in the cytoplasmic, nuclear and chromatin-associated fraction as
determined via DAVID (Huang et al., 2009). D) Scatter plot of fold changes heavy / light in the subcellular fractions of two independent SILAC experiments. Pearson
correlation between the two replicates is indicated in left top. Blue dots are proteins signiﬁcantly higher in serum ESCs in both replicates and green dots are proteins
signiﬁcantly higher in 2i ESCs (p < 0.05; signiﬁcance B). Diﬀerential proteins of interest have been highlighted. Bottom: Numbers and GO terms belonging to the
diﬀerential proteins (p < 0.05 using signiﬁcance B in both replicates) in the subcellular fractions. E) Venn diagram representing the overlap between identiﬁed
proteins (at least 2 peptides) in the various fractions. F) Venn diagrams representing the overlap between diﬀerential proteins in the various fractions. (For inter-
pretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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measured intracellular ROS levels, which revealed signiﬁcant higher
levels of ROS in 2i ESCs as compared to serum ESCs (Fig. 4E). As free
radicals can attack peptide backbones resulting in oxidized proteins,
this could implicate a higher presence of oxidized proteins in 2i ESCs.
To evaluate this, we used the dependent peptide search in Maxquant to
search for mono-, di- and trioxidized peptides (Savitski et al., 2006).
However, there was no signiﬁcant increase of oxidized proteins in 2i
ESCs (Fig. 4F).
To further investigate these ﬁndings, we assayed whether the in-
creased glutathione pathway proteins would reﬂect more eﬃcient ROS
buﬀering in 2i ESCs. To this end, we treated 2i and serum ESCs with the
chemical compounds doxorubicin (induction of DNA damage), 5-aza-
cytidine (induction of DNA hypomethylation) and MG132 (a protea-
some inhibitor), which all can induce intracellular ROS (Alexandrova
et al., 2008; Friesen et al., 1999; Gao et al., 2008). After exposure to
these compounds, we observed that the survival rate of 2i ESCs was
higher than that of serum ESCs. In addition, doxorubicin and 5-azacy-
tidine induced more ROS in serum ESCs as compared to 2i ESCs
(Fig. 4G-H, S2A-B), which further suggests that 2i ESCs are more eﬃ-
cient in eliminating ROS. Notably, although 2i ESCs showed better
survival to proteasome inhibition, this treatment did not induce ROS
(Fig. S2B), suggesting that this might be mediated through other me-
chanisms. To further substantiate the enhanced buﬀering capacity of 2i
ESCs, we added the same concentration of the radical H2O2 to the
culture medium of 2i and serum ESCs. This resulted in signiﬁcantly
more intracellular ROS in serum ESCs compared to 2i ESCs, further
demonstrating the enhanced metabolic buﬀering in 2i ESCs (Fig. 4I).
Unexpectedly, we observed a slightly compromised survival of 2i ESCs
to the addition of exogenous H2O2 as compared to serum ESCs (Fig.
S2C). As intracellular ROS levels in treated 2i ESCs were only margin-
ally higher compared to control cells, this is likely the result of inter-
ference of H2O2 with other processes or induction of damage to im-
portant cellular constituents such as the DNA. Altogether, these assays
reveal that 2i ESCs are more eﬃcient at buﬀering ROS.
The conversion of 2i to serum ESCs represents a powerful model for
in vivo development (Marks and Stunnenberg, 2014). Therefore, we
investigated whether the increased abundance of the proteins com-
prising the glutathione pathway is also observed in vivo. To this end, we
analyzed RNA-seq data generated from morula (E2.5), the Inner Cell
Mass (ICM, E3.5), preimplantation epiblast (E4.5) and post implanta-
tion epiblast (E5.5) (Boroviak et al., 2014). We observed that the ex-
pression of most subunits of the glutathione pathway was enriched in
the preimplantation stage. These included the glutathione peroxidase
(GPX1 and GPX4) and glutathione synthetase (GSS) which are critical
for the glutathione redox function as well as early embryonic devel-
opment (Winkler et al., 2011; Yant et al., 2003). On the other hand, the
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glycolysis pathway, which is enriched in serum ESCs, increases dra-
matically in the post implantation stage (Fig. 4J) (Boroviak et al., 2014;
Habibi et al., 2013). Taken together, these ﬁndings might indicate a
role for enhanced buﬀering against free radicals during early embryonic
development.
4. Discussion
SILAC-based workﬂows have been rapidly adopted in quantitative
proteomics because of the robustness and simplicity. A major advantage
of SILAC over label free proteomics (LFQ) or chemical labeling strate-
gies such as dimethyl labeling is that it allows for early mixing of
samples. This results in minimization of variation introduced during
sample preparation and enhanced precision and reproducibility of
quantiﬁcation (Lau et al., 2014). As such, SILAC is typically suited for
subcellular proteomics, which allows both studying molecular path-
ways as well as identiﬁcation of low-abundant proteins (e.g. plur-
ipotency and other transcription factors) through reduction of sample
complexity, which brings these proteins into the dynamic range of the
mass spectrometer (Graumann et al., 2008). Here, we show that SILAC
can be adopted for the subcellular comparison of 2i and serum ESCs.
This is particularly powerful with the use of 2i ESCs as these are grown
in chemically deﬁned medium in which normal (“light”) lysine and
arginine can conveniently be substituted by “heavy” lysine and argi-
nine. Here, we mixed 2i and serum ESCs prior to subcellular fractio-
nation, which minimizes variations introduced due to sample handling.
We observed a slight skewing of the non-normalized heavy/light ratios
towards the light channel, which is resolved upon normalization. For
future applications of the SILAC workﬂow, normalization of the mixing
on cellular level and protein level might be beneﬁcial to determine the
optimal experimental workﬂow.
Signiﬁcant eﬀorts have been made to disentangle the proteome of 2i
and serum ESCs (Taleahmad et al., 2015, 2017). Here we complement
these studies using SILAC-based quantitative subcellular proteomics,
which improves on the quantiﬁcation accuracy and simultaneously
increases the depth of the proteome. This allowed us to provide quan-
titative insights into the subcellular proteome of 2i and serum ESCs.
Among others, we investigated the pluripotency modules sustaining 2i
and serum ESCs. Previous reports demonstrated that 2i ESCs are char-
acterized by the upregulation of naïve pluripotency factors (Dunn et al.,
2014; Mzoughi et al., 2017; Qiu et al., 2015). Here, we provide evi-
dence that upregulation of these naïve factors in 2i ESCs is accompanied
by enrichment of these factors on chromatin. As such, a comprehensive
analysis of genomic binding sites of naïve factors such as TFCP2L1 and
TBX3 in 2i and serum ESCs might provide further insights into the
maintenance of the ground state of pluripotency. Next to factors that
characterize 2i ESCs, we identify pluripotency factors that are enriched
in serum ESCs, such as SALL4 and KLF5. It has been shown that Sall4
and Klf5 mutant ESCs grown in serum show strong signs of premature
diﬀerentiation. Therefore, it would be interesting to determine the
genomic locations of these factors in 2i and serum ESCs, as well as in
early diﬀerentiated cell types, to pinpoint the role of these factors in
pluripotency and the exit thereof.
The changes as we observe in the pluripotency network between 2i
and serum ESCs are likely to aﬀect the epigenetic state, as epigenetic
changes have been directly linked to relocalization of core pluripotency
factors (Galonska et al., 2015). In addition to the epigenetic environ-
ment, the pluripotency circuit has been found to orchestrate the me-
tabolic state of pluripotent stem cells. For example, ESRRB was shown
to enhance oxidative phosphorylation and is therefore essential for
reprogramming of somatic cells to naïve pluripotency. ZIC3 promotes
reprogramming towards primed pluripotency by enhancing glycolysis.
(Lim et al., 2007; Sone et al., 2017). The core pluripotency factor OCT4
was found to be directly involved in regulation of glycolysis and the
serum ESC speciﬁc factor MYC (Marks et al., 2012) has been linked to
the glutamine-dependence of serum ESCs (Carey et al., 2015; Wise
et al., 2008). Also LIN28A/B, direct targets of FGF signaling, have been
shown to modulate metabolic pathways towards glycolysis to facilitate
priming of ESCs (Zhang et al., 2016). Previous analyses on the RNA
level suggested that there might be diﬀerences in metabolism between
2i and serum ESCs (Marks et al., 2012). Here we extend these analyses
with quantitative information on the cytoplasmic proteome. Our ana-
lyses of the members of metabolic pathways indicated that serum ESCs
are enriched for glycolysis. However, previous observations revealed
similar use of the glycolysis pathway in 2i and serum ESCs (Carey et al.,
2015). As such, this indicates that serum ESCs are inducing transcrip-
tional networks that are required to fully switch to glycolysis metabo-
lism as characteristic for the in vivo post implantation epiblast as well as
epiblast-derived stem cells (EpiSCs) (Zhou et al., 2012). This further
supports the observation that serum ESCs represent a more primed
version of pluripotency compared to 2i ESCs and suggests that the en-
hancement of glycolysis is readily initiated upon dissolution of the
pluripotent ground state.
We show that 2i ESCs contain increased levels of proteins involved
in the glutathione pathway, as well as enhanced resistance to in-
tracellular ROS generation as compared to serum ESCs. As total levels of
glutathione itself are similar between 2i and serum ESCs, this suggests
that the turnover of oxidized and reduced glutathione, during which
ROS are scavenged, is more eﬃcient in 2i ESCs. This might be required
as 2i ESCs are metabolically more active and hence are likely to gen-
erate more free radicals during metabolic processes such as oxidative
phosphorylation as stimulated by ESRRB. Whether this is also relevant
for the preimplantation embryo remains to be investigated, although
our RNA-seq analysis indicates that the glutathione pathway is mostly
active before implantation. Interestingly, the formation of ROS, and
consequently the enhanced buﬀering, have been shown to aﬀect the
levels of DNA methylation (Wu and Ni, 2015). Given that 2i ESCs and
preimplantation embryos are hallmarked by global DNA hypomethy-
lation, it might well be that the enhanced glutathione metabolism in
ground state pluripotency contributes to epigenetic features such as
DNA hypomethylation.
Fig. 4. 2i ESCs are characterized by enhanced metabolic buﬀering. A) GO terms belonging to the diﬀerential proteins (p < 0.05) in the cytoplasmic fraction as
determined via the Metaboanalyst 3.0 software. GO terms visualized were enriched in either 2i or serum ESCs. (p < 0.05). B) Log2 fold change of glycolysis-
associated proteins. PDK1 and LDHA localize mainly in the cytoplasm, ZIC3 on the chromatin. Thus, data for PDK1 and LDHA was obtained from the cytoplasmic
fraction, data for ZIC3 from chromatin fraction. * indicates p < 0.05 in both experiments. C) Top: schematic overview of ROS scavenging. Bottom: heatmap
representing the log2 fold changes 2i / serum of two independent SILAC experiments. * indicates p < 0.05 in both experiments. Note that the Thioredoxins involved
here are TrxR (Thioredoxin reductases). D) Fluorescence measurement of total glutathione levels in 2i and serum ESCs. n.s. = not signiﬁcant. E) Fluorescence
measurement of ROS levels in 2i and serum ESCs. *= p < 0.05 (t-test). F) Distribution of log2 fold changes 2i / serum of mono-, di- or trioxidized peptides in the
cytoplasmic fraction as determined by the dependent peptide search in MaxQuant. Only peptides with an MS/MS count> 1 were included. n.s. = not signiﬁcant. G-
H) Top: Survival of 2i and serum ESCs relative to untreated control after 20-h treatment with doxorubicin (G) or with 5-azacytidine (H). Bottom: ROS production
after 3-h exposure to the compounds (500 nM doxorubicin, 1 μM 5-azacytidine) relative to DMSO treated control cells. *= p < .05 (t-test). I) Intracellular ROS
levels after treatment of 2i and serum ESCs with 150 μM H2O2 for 3 h. *= p < .05 (t-test). J) Gene expression of genes related to ROS scavenging and glycolysis in
preimplantation cells (E2.5-E4.5) and post implantation cells (E5.5). Row values are normalized using Z-scores. Genes indicated in red have a peak expression in
preimplantation cells, those in black have a peak expression in post-implantation development, genes in gray are similar in expression in pre- and postimplantation
embryos.
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5. Concluding remarks
In this work we present a SILAC workﬂow to reliably generate
subcellular proteomes of pluripotent states represented by mouse em-
bryonic stem cells (ESCs) maintained in distinct culture media. Using
SILAC, we show that the pluripotent ground state as presented by 2i
ESCs is hallmarked by distinct metabolic programs as compared to
more primed serum ESCs. Future studies using in-depth metabolomics
proﬁling will be required to further investigate the metabolic programs
as identiﬁed here and how these contribute to ground state plur-
ipotency. Moreover, the application of this SILAC workﬂow can be used
to comprehensively study the molecular pathways sustaining plur-
ipotency, for example through combining subcellular fractionation with
phospho- or ubiquitin-proteomics, which could uncover novel signaling
cascades. Furthermore, SILAC could be applied in proteomic compar-
isons of 2i and serum ESCs for which early mixing of cells is highly
beneﬁcial, such as organelle enrichment and interactome studies (Li
et al., 2012).
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.scr.2018.09.017.
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